Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Cash from Financing Activities (2020 - 2025)

Rani Therapeutics Holdings has reported Cash from Financing Activities over the past 6 years, most recently at $44.9 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $44.9 million for Q4 2025, up 698.22% from a year ago — trailing twelve months through Dec 2025 was $40.3 million (up 196.65% YoY), and the annual figure for FY2025 was $40.3 million, up 196.65%.
  • Cash from Financing Activities for Q4 2025 was $44.9 million at Rani Therapeutics Holdings, up from -$1.0 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for RANI hit a ceiling of $71.5 million in Q3 2021 and a floor of -$3.7 million in Q1 2025.
  • Median Cash from Financing Activities over the past 5 years was $121000.0 (2024), compared with a mean of $8.4 million.
  • Biggest five-year swings in Cash from Financing Activities: soared 15622.45% in 2024 and later plummeted 3183.47% in 2025.
  • Rani Therapeutics Holdings' Cash from Financing Activities stood at -$570000.0 in 2021, then soared by 2709.47% to $14.9 million in 2022, then crashed by 99.35% to $96000.0 in 2023, then skyrocketed by 5753.12% to $5.6 million in 2024, then surged by 698.22% to $44.9 million in 2025.
  • The last three reported values for Cash from Financing Activities were $44.9 million (Q4 2025), -$1.0 million (Q3 2025), and $188000.0 (Q2 2025) per Business Quant data.